January 15, 2020
Healthpeak Properties, Inc. (NYSE: PEAK) has signed Janssen BioPharma, Inc., a Johnson & Johnson subsidiary, to a long-term lease for approximately 60% of Phase II at The Shore at Sierra Point in Brisbane, CA. Janssen BioPharma has expansion rights under the lease that can be exercised over the course of 2020.
Phase II of The Shore at Sierra Point includes two Class A purpose-built life science buildings within a larger five-building campus for a total of 298,000 square feet. The lease is expected to commence in January 2022, upon completion of construction.
“We are excited to grow our long-term partnership with the Johnson & Johnson Family of Companies,” said Tom Herzog, Healthpeak’s CEO. “The Shore at Sierra Point will be one of the flagship campuses within our differentiated life science portfolio.”